Kestra Medical Technologies Ltd (KMTS) FinancialsKMTSFinancialKestra Medical Technologies Ltd

Evaluating the bottom line, Kestra Medical Technologies, Ltd. maintains a gross margin of 54.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -137.38%, while the net margin is -135.61%. These profitability ratios, combined with a Return on Equity (ROE) of -56.60%, provide a clear picture of how effectively KMTS converts its operational activities into shareholder value.

In the context of the broader market, KMTS competes directly with industry leaders such as CNMD and TNDM. With a market capitalization of $1.64B, it holds a leading position in the sector. When comparing efficiency, KMTS's gross margin of 54.76% stands against CNMD's 57.49% and TNDM's 56.87%. Such benchmarking helps identify whether Kestra Medical Technologies, Ltd. is trading at a premium or discount relative to its financial performance.

Kestra's revenue has been increasing, with Q2 2026 revenue at $22,565,000, up from $19,371,000 in Q1 2026. Gross margin has improved significantly, reaching 54.76% in Q4 2026, up from 39.63% in Q2 2025, indicating better cost management and pricing power.